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Introductory paragraph  
It is now well established that tumours undergo changes in cellular metabolism1.  As 
this can reveal tumour cell vulnerabilities and because many tumours exhibit enhanced 
glucose uptake2, we have been interested in how tumour cells respond to different forms 
of sugar.  Here we report that the monosaccharide mannose causes growth retardation 
in multiple tumour types and enhances cell death in response to major forms of 
chemotherapy.  Importantly, we go on to show that these effects also occur following 
oral administration of mannose in vivo without significant impact on animal weight and 
health.  Mechanistically, mannose is taken up by the same transporter(s) as glucose3, 
but accumulates as mannose-6-phosphate in cells and this impairs the further 
metabolism of glucose in glycolysis, the TCA cycle, the pentose phosphate pathway and 
glycan synthesis.  As a result, when used in combination with conventional 
chemotherapy, this has an impact on protein levels of anti-apoptotic members of the 
Bcl-2 family leading to sensitization to cell death.  Finally, we show that susceptibility to 
mannose is dependent on the levels of phosphomannose isomerase (PMI).  Cells with 
low levels of PMI are sensitive to mannose, whereas cells with high levels are resistant, 
but can be made sensitive by RNAi-mediated depletion of the enzyme.  In addition, we 
show using tissue microarrays that PMI levels also vary greatly between different 
patients and different tumour types, indicating that PMI levels could be used as a 
biomarker to direct successful mannose administration.  When taken together, we 
consider that treatment with mannose could be a simple, safe and selective way to treat 
cancer applicable to multiple tumour types.   
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As tumours often have a high avidity for glucose4, we examined the impact of other sugars on 
tumour cell growth.  This revealed that mannose, in contrast to other sugars, significantly 
reduced U2OS cell growth (Fig. 1a).  Similar effects occurred in Saos-2 cells, with fucose 
also causing a comparatively small decrease in cell growth (Extended Data Fig. 1a).  Using a 
panel of cell lines, we observed that this effect of mannose occurs in cells from various 
tissues, with the impact being greater in some cells than others (Fig. 1b,c, Extended Data Fig. 
1a-d). 
 
Mannose is imported into cells via the same transporters as glucose3, so we considered 
mannose may interfere with glucose uptake. Supporting this hypothesis, we observed that 
mannose enhances phospho-AMPK levels – a readout of energy balance in cells5,6 (Extended 
Data Fig. 1e).  However, liquid chromatography-mass spectrometry (LC-MS) showed that 
levels of the phosphorylated form of the glucose analogue 2-deoxyglucose (2-DG-P), used as 
a proxy for glucose uptake, did not correlate with mannose sensitivity in mannose-sensitive 
versus insensitive lines (Figure 1a,b; Extended Data Fig. 1f,g), and mannose actually 
increased the intracellular pool of hexose-6-phosphate (the first step in metabolism of glucose 
and mannose) (Extended Data Fig. h).  This effect was not observed with other sugars 
(Extended Data Fig.1i).  
 
To determine if the mannose-induced increase in hexose-6-phosphate is due to mannose or 
glucose, we performed LC-MS with an extended chromatography time to enable selective 
detection of the unphosphorylated form of these sugars.  This revealed that mannose 
increased the intracellular pool of mannose, as expected, but also increased the intracellular 
pool of glucose (Extended Data Fig. 1j, k).  To corroborate, we treated cells with glucose 
labelled with two atoms of 13C (1,2-13C2-Glucose) and mannose labelled with six atoms of 
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13C (13C6-Mannose) to enable detection due to differences in molecular mass and we again 
found that mannose treatment increased intracellular glucose levels (Extended Data Fig. 1l). 
 
As mannose did not reduce intracellular glucose, but significantly impacted cell growth, we 
considered it may interfere with glucose metabolism.  There is considerable crosstalk 
between the metabolism of these sugars and mannose-6-phosphate can inhibit three enzymes 
that mediate glucose metabolism: hexokinases, phosphoglucose isomerase (PGI) and glucose-
6-phosphate dehydrogenase (G6PDH)7 (Fig. 1d).  To address this possibility, we measured 
the levels of hexose-6P and lactate when cells were incubated in glucose-free medium 
supplemented with either 1,2-13C2-Glucose or 13C6-Mannose.  This revealed that mannose 
accounts for more of the mannose-induced hexose-6P accumulation than glucose, but also 
that glucose-6P is produced in the presence of mannose, albeit at reduced levels when 
compared with cells treated with glucose alone (Fig. 1e).  We also observed that mannose 
does not produce much lactate (indicating it is poorly metabolised) and more importantly, 
that mannose markedly reduces lactate production from glucose (Fig. 1f).  Further analysis 
revealed that mannose treatment not only affects pools of glycolytic intermediates, but also 
those involved in the TCA cycle, pentose phosphate pathway and glycan synthesis (Fig. 1g-i).  
As with the effects on cell growth, these metabolic effects were not observed with other 
sugars (Extended Data Fig. 1m-p).  Moreover, while mannose uptake was not lower in 
mannose-insensitive cells when compared to sensitive cells (Extended Data Fig. 2a), the 
effects of mannose on metabolism were only observed in cells sensitive to the sugar 
(Extended Data Fig. 2b-h).  Interestingly, we also found that mannose-induced AMPK 
phosphorylation does not concomitantly occur with changes in the levels of AMP or ATP, 
but is associated with a decrease in Fructose-1,6-bisphosphate levels as recently described6 
(Extended Data 3a-f). 
5 
 
 
Because mannose affects tumour cell growth, we questioned whether it can also affect the 
cellular response to chemotherapeutic drugs.  While mannose alone did not affect cell 
viability, it significantly enhanced cell death when administered with cisplatin or doxorubicin 
- an effect not seen with other hexoses (Figs 2a,b; Extended Data Fig. 4a-c).  Mechanistically, 
the combination of mannose and chemotherapeutic drug increased the levels of cleaved 
PARP (a substrate of caspase-38) and this effect, together with death, was blocked by the pan-
caspase inhibitor zVAD-fmk (Fig. 2c,d; Extended Data Fig. 4d).   
 
As our data indicated that cell death from mannose and chemotherapeutic drug likely 
proceeds by apoptosis, we utilised CRISPR/Cas9 to determine which apoptotic pathways 
might be involved. Disruption of caspase 8 and FADD – two components of the extrinsic 
apoptotic pathway9  –had no impact on the cell death observed (Extended Data Fig. 4e-g).  In 
contrast, disruption of Bax and Bak  - essential factors for mitochondrial outer membrane 
permeabilisation (MOMP) and the intrinsic pathway10  – significantly blocked death from 
mannose in combination with either cisplatin or doxorubicin (Fig. 2e; Extended Data Fig. 
4h,i).   
 
MOMP is controlled by Bcl-2 family members,11 so we examined the levels of these proteins 
in the presence of mannose, cisplatin or in combination.  In line with previous studies 
detailing a role for the Noxa/Mcl-1 axis in glycolysis inhibition and glucose deprivation,12-14 
we found Noxa was increased by cisplatin and cisplatin plus mannose, and Mcl-1 and Bcl-XL 
were reduced by the combination treatment (Fig. 2f; Extended Data Fig. 4j).  
Mechanistically, we consider Mcl-1 and Bcl-XL are diminished through decreased translation 
as they decreased in the presence of proteasome inhibitor and their mRNAs were not reduced 
6 
 
by the combination treatment (Extended Data Fig 2k-m).  Involvement of these proteins was 
confirmed by CRISPR-mediated disruption of noxa or by over-expression of Mcl-1 or Bcl-
XL, which all repressed death induced by mannose and chemotherapy (Fig. 2g,h; Extended 
Data Fig. 4n-q; Extended Data 5a).  Finally, we also observed that mannose enhances death 
induced by the Bcl-XL antagonist WEHI539, but not the Bcl-2 antagonist ABT-199 
(Extended Data Figure 5b).   
 
We were keen to know if mannose also has effects in vivo.  Tumour-bearing mice were 
therefore given a single oral gavage of mannose, which resulted in a serum concentration of 
approximately 3mM (Extended Data Fig. 6a).  Animals were then injected with 2-deoxy-2-
(18F)fluoro-D-glucose (18F-FDG) to monitor 18F-FDG uptake and its subsequent conversion 
by hexokinases into 18F-FDG-6-P15.  As mannose impedes hexokinases6, we found it 
significantly reduced the 18F-FDG signal (provided by 18F-FDG and/or 18F-FDG-6-P) when 
tumours of equivalent size in each condition were compared (Fig. 3a; Extended Data Fig. 
6b,c).  A significant effect on the 18F-FDG signal was also seen in certain normal tissues 
(Extended Data Fig. 6d).   
 
To test if mannose could affect tumour growth, animals were injected with tumour cells 
subcutaneously and given mannose by oral gavage 3 times per week and ad libitum in 
drinking water.  This did not affect animal weight, nor did it visibly affect animal health, 
(Extended Data Fig. 6e), but it significantly inhibited tumour growth (Fig. 3b), involving 
decreased numbers of BrdU-positive cells, indicating that mannose inhibits cell proliferation 
both in vitro and in vivo (Extended Data Fig. 6f,g). 
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We were also interested to know if mannose can also enhance chemotherapy in vivo.  
Tumour-bearing nude mice were therefore treated with mannose and doxorubicin either alone 
or in combination.  While none of the treatments affected the weight or visible health of the 
animals (Extended Data Fig. 6h), we found that either doxorubicin or mannose caused a 
reduction in tumour volume (Fig. 3c).  Moreover, when doxorubicin was administered in 
combination with mannose an even greater effect was observed (Fig. 3c).  Importantly, when 
we examined the overall survival of the treated cohorts, those treated with doxorubicin plus 
mannose had a significantly increased life expectancy when compared to untreated mice or 
those treated with either doxorubicin or mannose alone (Fig. 3d). 
 
As our data indicated that mannose could potentially be used clinically, we wanted to 
understand why different cells vary in their sensitivity to the sugar.  Because mannose affects 
several metabolic pathways, we reasoned that sensitivity may be connected to an apical 
enzyme involved in sugar metabolism.  Our profiling revealed that mannose sensitivity was 
roughly inversely correlated with the levels and activity of phosphomannose isomerase (PMI) 
- the enzyme that catalyses the interconversion of mannose-6P and fructose-6P16  (Fig 4a; 
Extended Data Fig. 7a; Fig. 1a-c; Extended Data Figure 1 b-d,f).   Consequently, we 
knocked-down PMI in 3 mannose-insensitive cell lines – SKOV3, RKO and IGROV1.  In 
each case, PMI knockdown caused growth retardation upon mannose treatment (Fig. 4b; 
Extended Data Fig. 7b-g) and dramatically sensitized cells to cell death when mannose was 
administered together with cisplatin (Fig. 4c).  Conversely, PMI over-expression in a 
mannose-sensitive line rendered the line refractory to the effects of mannose on both cell 
growth and cell death (Fig. 4d; Extended Data Fig. 7h-k).  Finally, we found that mannose 
treatment following PMI knockdown had highly significant effects on metabolic pathways 
downstream of the sugar (Fig 4e; Extended Data Fig. 7l-o).   
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We next questioned if PMI could be modulated to affect the response of tumours to mannose 
in vivo. Since the immune microenvironment is important in many therapeutic situations and 
because mannose can affect immune cell function17,18, we decided to utilize immune-
competent mice and two syngeneic cell lines (B16-F1 and LLC) which are ordinarily 
mannose-insensitive, but which become sensitive upon PMI knockdown (Fig. 4f,g; Extended 
Data Fig. 8a-d).  In both cases, allografts formed with PMI knockdown cells were highly 
sensitive to oral administration of mannose (Fig. 4h-k), without visibly affecting animal 
health or weight (Extended Data Fig. 8e-h) 
 
We were also interested to know if PMI levels varied in human tumours such that analysis of 
PMI could potentially be used as a biomarker for mannose sensitivity.  We therefore stained 
tissue microarrays (TMAs) containing sections from ovarian, renal, breast, prostate and 
colorectal cancers.  This revealed that PMI levels varied between tumours from the same 
tissue and also between tissues (Fig. 4l; Extended Data Fig. 9a).  PMI levels did not, 
however, have prognostic significance in breast and colon cancer, presumably because 
normal serum levels of mannose are low compared to glucose19(Extended Data Fig. 9b-d).  
 
Most notable from our analyses was the fact that colorectal tumours generally have very low 
PMI levels, indicating they may be broadly sensitive to mannose.  To explore this, we utilised 
an inflammation-driven model of colorectal cancer and a genetically engineered mouse 
model (GEMM) driven by two genes frequently altered in this disease (K-Ras and APC)20.  
In both models, mice maintained on drinking water containing 20% mannose had 
significantly fewer tumours at endpoint (Fig. 4m,n) and importantly, mannose had no 
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negative impact on the health or weight of the animals over the time examined (Extended 
Data Fig. 9e,f). 
 
In contrast to the effects on glucose metabolism, mannose does not decrease amino acid or 
fatty acid uptake and while mannose reduces glucose-dependent serine and glycine synthesis, 
this contributes only marginally to total cellular serine and glycine pools (Extended Data Fig. 
10a-f).  Mannose also affects transcription, translation and autophagy, but these effects were 
reversed by PMI over-expression, indicating they are downstream of glucose metabolism 
(Extended Data Fig. 10g-l).  Moreover, ablation of autophagy did not affect mannose 
sensitivity showing that autophagy inhibition is not the mechanism underlying the effects of 
the sugar (Extended Data Fig. 10m,n).  In summary, we conclude that mannose represents a 
well-tolerated means to interfere with glucose metabolism that could potentially be used 
clinically either alone or in combination with other forms of cancer therapy. 
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Figure Legends 
 
Figure 1: Mannose impairs cancer cell growth and interferes with glucose metabolism 
by accumulating as mannose-6-phosphate intracellularly. (a) Growth curves of U2OS 
cells supplemented without (Ctrl) or with 25mM of hexoses (Man, mannose; Gal, galactose; 
Fru, fructose; Fuc, fucose; Glc, glucose). (b-c) Growth curves of (b) Saos-2 cells in DMEM (-
Man) or with additional 25mM mannose (+Man) and (c) KP-4 cells in IMDM medium with 
or without 25mM mannose. (d) Scheme of mannose metabolism: mannose enters the cells 
using the same (GLUT) transporters as glucose and it is phosphorylated into mannose-6-
phosphate by hexokinases (HK). Mannose can then be used for glycosylation purposes or 
isomerized into fructose-6-phosphate by phosphomannose isomerase (PMI). Glucose-6-
phosphate can also produce mannose-6-phosphate by phosphoglucose isomerase (PGI) and 
PMI. Mannose-6-phosphate also participates in the biosynthesis of deaminoeuraminic acid 
(KDN). (e,f) Extraction of intracellular metabolites and measurement of the peak area per 
microgram of protein of (e) glucose-6-phosphate (m+2) and mannose-6-phosphate (m+6) and 
(f) lactate (m+0, m+2, m+3) after 6 hours incubation of U2OS cells in 10% dialyzed FBS 
glucose-free DMEM complete medium in the presence of 5mM 1,2-13C2-D-glucose alone and 
or 5mM 13C6-D-mannose. (g-i) Percentage of peak area per microgram of protein of 
intracellular metabolites (g) glyceraldehyde-3-phosphate (GA3-P) and phosphoenolpyruvate 
(PEP); (h) α-ketoglutarate (α-KG) and malate; (i) ribose-5-phosphate (Ribose-5P) and UDP-
N-Acetyl-glucosamine (UDP-GlcNAc) post 6-hours incubation of U2OS cells in 10% 
dialyzed FBS 5mM glucose DMEM complete medium with or without 5mM mannose. n=3 
independent experiments (a,b,c,g,h,i). Data are representative of three independent 
experiments (e,f).  Data are mean +/- S.E.M..  Data were analysed by (a-c) two-way ANOVA 
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with Bonferroni correction or (g-i) paired two-tailed Student’s t-test. *P < 0.05, **P < 0.01, 
***P < 0.001.  
 
Figure 2: Combination of chemotherapy with mannose enhances cell death by 
potentiating the intrinsic pathway of apoptosis through the downregulation of Mcl-1 
and Bcl-XL protein levels. (a-h) All experiments were performed by pre-incubating cells in 
the presence of complete DMEM or 25mM sugars-supplemented complete DMEM for 24 
hours prior to addition of other treatments. (a-b) Percentage of U2OS-E1a and Saos-2 
propidium iodide (PI)-positive cells after 24 h treatment with (a) 10µM cisplatin and (b) 
1µg/mL of doxorubicin in the presence or absence of 25mM mannose. (c) Percentage of 
U2OS-E1a PI-positive cells treated for 24 hours with or without 10µM cisplatin, with or 
without 25mM mannose and with or without 10µM of the caspase inhibitor zVAD-fmk. (d) 
Western blotting showing the levels of cleaved PARP and cleaved caspase-3 in U2OS-E1a 
cells after 24 hours treatment with or without 10µM cisplatin, with or without 25mM 
mannose and with or without 50µM zVAD-fmk. (e) Percentage of Empty and Bax/Bak 
CRISPR U2OS-E1a PI-positive cells treated with or without 10µM cisplatin for and with or 
without 25mM mannose for 24 h. (f) Western blotting showing the levels of Mcl-1, Bcl-XL 
and cleaved caspase-3 in U2OS-E1a cells after 24h with or without 10µM cisplatin, with or 
without 25mM mannose and with or without 50µM zVAD-fmk.  (g,h) Percentage of PI-
positive U2OS-E1a (Emtpy, Mcl-1 and Bcl-XL overexpressing) cells after 24 h treatment 
with or without 10µM cisplatin and with or without 25mM mannose. n=3 independent 
experiments (a,b,c,e,g,h). Data are representative of three independent experiments (d,f).  
Data are mean +/- S.E.M.. Data were analysed by (a,b,c,e,g,h) two-way ANOVA with 
Bonferroni correction. *P < 0.05, **P < 0.01, ***P < 0.001.  
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Figure 3: Mannose impairs tumour growth and induces tumour regression in 
combination with chemotherapy. (a) CD1-nude mice were transplanted with KP-4 cells 
subcutaneously and tumours were grown for 14 days before PET-MRI imaging. (a) PET-MRI 
scan of mice treated with 200µL of water (-Man) or 20% (w/v) mannose in water (+Man) by 
oral gavage 20 min before 18F-FDG tail vein injection. White dotted circles highlight tumour 
areas in axial view of the mice. (b) CD1-nuce mice were injected with KP-4 cells 
subcutaneously and treated with normal drinking water (-Man) or 20% mannose in the 
drinking water (w/v) plus the same treatment via oral gavage 3 days per week from the 3rd 
day after tumour transplantation. Tumour volume (mm3) was measured as indicated. (c,d) 
CD1-nude mice were injected with KP-4 cells subcutaneously and tumours were grown for 
10 days before mannose treatment started. Mice received normal drinking water (Ctrl and 
Doxo) or 20% mannose in the drinking water (Man and Doxo + Man) together with the same 
treatment via oral gavage 3 days per week. Doxorubicin treatment started on day 32 and mice 
received 5mg/kg by IP injection once per week. (c) Tumour volume (mm3) of all groups of 
treatment. (d) Graph representing the survival of the animals in all groups of treatment until 
the end of the experiment at day 73. Mice number for each experiment is (a) n=5, -Man; n=4, 
+Man, (b) n=10, -Man; n=8, +Man (c,d) n=10/group.  Data are mean +/- S.E.M..  Data were 
analyzed by two-way ANOVA with Bonferroni correction (b,c) or log-rank (two-sided 
Mantel-Cox) (d). **P < 0.01, ***P < 0.001.  
 
Figure 4: PMI levels dictate mannose sensitivity. (a) Western blot showing the levels of 
PMI and ERK2 in a panel of 10 cancer cell lines. (b) Growth curves of SKOV3 cells in 
complete DMEM medium with or without supplementation of 25mM mannose after transient 
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transfection with 2 non-targeting (NTC) and 2 PMI targeting siRNAs individially for 48 
hours. (c) Cell death represented as percentage of PI-positive SKOV3 siRNA transfected 
cells pre-incubated with or without 25mM mannose in regular DMEM for 24 hours before 
adding 10µM of cisplatin for another 24 h. (d) Over-expression of PMI makes U2OS 
insensitive to mannose.  Growth curves of U2OS overespressing PMI (U2OS-PMI) and cells 
expressing vectrol control (U2OS) after culture in either in DMEM (black line) or DMEM 
containing 25mM mannose (blue line).  (e) Percetange of hexoses-6P metabolic content in 
SKOV3 transfected cells with siRNA for 48 h before 6 h incubation in complete DMEM 
medium with or without supplementation of 25mM mannose.  (f,g)  Knockdown of PMI 
renders B16-F1 and LLC cells sensitive to mannose.  The indicated cell were incubated with 
or without 25mM mannose for 24h before cell counting.  (h-k) B16-F1 or LLC cells 
expressing PMI-targeting or control shRNAs were injected into the flanks of C57BL/6 mice.  
Animals were maintained either with or without 20% mannose in drinking water and tumour 
growth was monitored over time (n=10 mice per group).  (l) PMI expression levels in tissue 
microarrays from  ovarian (n=45), renal (n=180), breast (n=159), prostate (Prost.)(n=155) and 
colorectal (Colorect.)(n=216) tumours. (m) Mice (n=14/group) were subjected to AOM/DSS 
treatment for 68 days.  Animals were treated with normal drinking water or with 20% (w/v) 
mannose in the water until the end of the experiment. Tumours were counted in the colon of 
each mouse. (n) VillinCreER Apcfl/+ KrasG12D/+ mice were aged until clinical end-point. Mice 
were treated with normal drinking water or with 20% (w/v) mannose in water from four days 
post-induction until the end of the experiment (n=9 animals, - Mannose; n=8 animals, + 
Mannose). Tumours were counted in the colon of each mouse. n=3 independent experiments 
(b,c,e,f).  n=5 independent experiments (d).  Data represent one independeent experiment 
with technical triplicate (g) or are representative of two independent experiments (a).  Data 
are mean +/- S.E.M..  Data analyzed by one-sided Mann-Whitney U test  ***P < 0.001.  Data 
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were analyzed in (c,e) by two-way ANOVA with Bonferroni correction, (d) multiple two-
sided unpaired t-test with Holm-Sidak correction (h-k) two-way ANOVA with Tukey 
correction, (l) one-way ANOVA with Bonferroni correction and (m) unpaired two-tailed 
Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001. ****P < 0.0001 
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Methods (online-only) 
 
Cell culture, transfections and infections 
All cell lines were from Beatson Institute stocks and were originally obtained from ATCC, 
ECACC repositories apart from PATU-8902 (DMSZ, Cat#: ACC-179) and KP-4 ((RIKEN, 
Cat#: RCB1005).  The following cells - A549, IGROV-1, Saos-2, U2OS, U2OS-E1a, SKOV-
3, RKO, PATU-8902 – were grown in DMEM high glucose supplemented with 10% FBS, 
0.292 mg/ml Glutamine and Penicillin (100 Units/ml)/Streptomycin (100g/ml) (all from 
Life Technologies). U2OS-E1a cells generated in our laboratory and have been previously 
described21.  K562 cells were grown in RPMI-1640 and KP-4 were grown in IMDM (Life 
Technologies) 20% FBS supplemented with Penicillin (100 Units/ml)/Streptomycin 
(100g/ml).  B16-F1 mouse skin melanoma cell line was a gift from Laura Machesky 
(Cancer Research UK Beatson Institute, UK) and were maintained in DMEM (Thermo Fisher 
Scientific, Cat#: 21969035) supplemented with 10% FBS (Thermo Fisher Scientific, Cat#: 
10270106), 2 mM L-Glutamine (Thermo Fisher Scientific, Cat#: 25030032), and Penicillin-
Streptomycin (Thermo Fisher Scientific, Cat#: 15140122). LLC mouse Lewis lung carcinoma 
cells were a gift from Sara Zanivan (Cancer Research UK Beatson Institute, UK) and were 
maintained in RPMI-1640 (Thermo Fisher Scientific, Cat#: 31870074), 10% FBS, 10mM 
HEPES (Thermo Fisher Scientific, Cat#: 15630080), 2mM L-Glutamine, and Penicillin-
Streptomycin. These cell lines were confirmed to be free of mycoplasma.  
 
Cells were transfected using Calcium Phosphate precipitates as previously described16. U2OS 
cells were infected with virus containing pBabe-puro-empty or pBabe-puro-Bcl-XL following 
the same protocol as previously published21. U2OS cells were infected with virus containing 
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pLZRS empty or pLZRS HA-Mcl-1 (kindly provided by Stephen Tait)22. U2OS infected cells 
were selected in DMEM 10% FBS containing 600µg/mL of neomycin for 2 weeks. U2OS 
control and Bax/Bak CRISPR cells were kindly provided by Stephen Tait. 
The following siRNAs were used: 
PMI siRNA-1 (Dharmacon.  catalog number: J-011729-05-0002),  
PMI siRNA-2 (Dharmacon.  catalog number: J-011729-06-0002),  
PMI siRNA-3 (Dharmacon.  catalog number: J-011729-07-0002), 
PMI siRNA-4 (Dharmacon.  catalog number: J-011729-08-0002).  
NTC1 (Dharmacon.  catalog number: D-001810-03-20), 
NTC2 (Dharmacon.  catalog number: D-001810-04-20. 
 
lentiCRISPR v2 was a gift from Feng Zhang (Addgene plasmid #5296123. The following 
sgRNA sequences were used in the experiments.  
NTC 1: GTAGCGAACGTGTCCGGCGT  
NTC 2: GCTTGAGCACATACGCGAAT  
ATG5: AAGAGTAAGTTATTTGACGT  
ATG7: GAAGCTGAACGAGTATCGGC  
Casp8  GCCTGGACTACATTCCGCAA    
FADD  TTCCTATGCCTCGGGCGCGT       
BAX   AGTAGAAAAGGGCGACAACC   
BAK  GCCATGCTGGTAGACGTGTA        
NOXA  TCGAGTGTGCTACTCAACTC 
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pGIPZ-non-targeting control (NTC) (Cat#: RHS4346), PMI #1 (Cat#: RMM4431-
200352145, Clone ID: V2LMM_110673), and PMI #2 (Cat#: RMM4431-200355616, Clone 
ID: V2LMM_203337) shRNAs were purchased from Dharmacon.  
pLX304 was a gift from David Root (Addgene plasmid #25890). Human PMI cDNA was 
amplified using pCMV-Sport-MPI (Dharmacon cat no: MHS6278-202802339) as a template 
and inserted into pDONR221 vector (Thermo Fisher Scientific, Cat#: 12536017) using 
Gateway BP Clonase II Enzyme mix (Thermo Fisher Scientific, Cat#: 11789020). PMI 
cDNA was then transferred into pLX304 destination vector using Gateway LR Clonase II 
Enzyme mix (Thermo Fisher Scientific, Cat#: 11791020). 
Lentivirus production and infection were carried our as described before24. 
 
Cell culture treatments. 
Mannose treatment 
Cells were seeded in 6-well plates and incubated overnight at 37⁰C. The following day, the 
medium was replenished with fresh full growth medium (DMEM, RPMI or IMDM) 
containing 25mM Mannose (when DMEM or IMDM) or 11.11mM Mannose (when RPMI). 
Other sugars were added at 25mM concentration: D-glucose (Sigma, G8270), D-fructose 
(Sigma F3510), D-galactose (Sigma G5388), L-Fucose (Sigma F2252 and Cayman chemical 
16479). New stocks were prepared every two weeks of 1M Mannose in milliQ water and 
sterilised by filtering through a 0.22µm pore filter. For control conditions, the same volume 
of milliQ water was added to the medium. Cells were left for at least 24 hours for cell death 
experiments or for 6 hours for metabolic experiments.  Cell death was blocked by treatment 
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with zVAD-fmk (Apax Labs, A1902).  2-Deocy-D-glucose (Sigma-Aldrich, Cat#: D8375), 
Tunicamycin (Sigma-Aldrich, Cat#: T7765), Chloroquine (Sigma-Aldrich, Cat#: C6628). 
13C-labelled sugars 
Cells were seeded and the following day washed 3 times with abundant PBS before adding 
glucose-free DMEM (supplemented with 10% dialyzed FBS, 2mM glutamine, 100 Units/ml 
of penicillin and 100 µg/ml of streptomycin). This medium could contain 5mM of 1,2-13C2-
glucose alone, together with 13C6-mannose or 5mM 13C6-mannose alone. Stocks of 1,2-13C2-
glucose and 13C6-mannose were prepared at a concentration of 0.5M in milliQ water prior to 
sterilization by filtering through a 0.22µm pore filter. 
Chemotherapeutic drugs 
Cells were plated overnight and were then incubated for the times indicated in control or 
mannose-containing medium. After one day incubation, fresh control and mannose-
containing media were prepared and drugs were added as described for each experiment. 
Drugs used were: Cisplatin (Sigma; C2210000), doxorubicin (Sigma; D1515).   
Western blotting 
Protein extraction was performed as previously described25. Protein lysates were separated by 
SDS-PAGE and blotted onto Nitrocellulose membranes. Western blot analysis was 
performed according to standard techniques as previously described25. The following 
antibodies were used at a 1/1000 dilution unless otherwise stated: β-Actin (Abcam; ab8227), 
Mcl-1 (Cell signaling; 4572), ERK2 (Santa Cruz; sc-154), Bcl-XL (Cell signaling; 2762), 
HSP-90β (Santa Cruz; sc-1057), PARP (Cell signalling; 9542), Cleaved-caspase-3 (Cell 
signalling; 9664), FADD (Transduction labs; F36620), Caspase-8 (Cell signalling; 4790), 
Bax (Transduction labs; 610983), Bak (Cell signalling; 6947), Bim (Cell signalling; 2993), 
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Noxa (Novus Biologicals; NB-600-1159), phospho-AMPKα (Cell signalling; 2535), AMPKα 
(Cell signalling; 5832), PMI (Abcam; 128115).  LC3B (Cell Signaling Technology, Cat#: 
2775S, 1/1500), -actin (Cell Signaling Technology, Cat#: 4670S, 1/2000), ATG5 (Cell 
Signaling Technology, Cat#: 12994S), ATG7 (Cell Signaling Technology, Cat#: 8558S), 
Bip/GRP78 (Cell Signaling Technology, Cat#: 3177S), p62 (BD Biosciences, Cat#: 610833, 
1/2000). Mouse PMI protein was detected using rabbit polyclonal PMI antibody (Proteintech, 
Cat#: 14234-1-AP).  Validation was based on information provided in manufacturers’ 
datasheets.  In addition, as indicated in the manuscript, we utilized RNAi or CRISPR/Cas9 to 
validate the following the antibodies used to detect the following proteins:  Bax, Bak, 
Caspase-8, FADD, PMI, Atg5 and Atg7. 
 
Metabolic extraction of intracellular metabolites 
Cells were seeded at a concentration of 100,000 cells/well in 6-well plates. The next morning, 
the medium was replenished with fresh full medium and cells were kept under this condition 
for another 24 hours to stabilise their metabolism. Approximately 36-40 hours after being 
plated, cells were treated under different conditions as described in results, using full growth 
medium or glucose-free with or without the presence of unlabelled sugars or labelled sugars 
for 6 hours. After 6 hours incubation at 37⁰C, intracellular metabolites were extracted. 
Medium was aspirated and 6-well plates were placed on ice and washed thoroughly with 4⁰C 
PBS 3 times before addition of 500µL extraction solvent (50% Methanol, 30% Acetonitrile, 
20% milliQ water) to each well. Plates were then agitated at 4⁰C for 5 min to successfully 
extract intracellular metabolites and then centrifuged at 16,100g for 10 min at 4°C.  
Supernatants were transferred into HPLC vials and stored at -80°C prior to LC-MS analysis.   
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An Exactive Orbitrap mass spectrometer (Thermo Scientific, Waltham, MA, USA) was used 
together with a Thermo Scientific Accela HPLC system.  The HPLC setup consisted of a 
ZIC-pHILIC column (SeQuant, 150 x 2.1mm, 5µm, Merck KGaA, Darmstadt, Germany), 
with a ZIC-pHILIC guard column (SeQuant, 20 x 2.1mm) and an initial mobile phase of 20% 
20mM ammonium carbonate, pH 9.4, and 80% acetonitrile.  Cell extracts (5µl) were injected 
and metabolites were separated over a 15 min mobile phase gradient, decreasing the 
acetonitrile content to 20%, at a flow rate of 200μL/min and a column temperature of 45°C.  
The total analysis time was 23 min.  For longer runsd of 37 min, a 30 min gradient with the 
same solbenst was used, at a flow rate of 100L/min and a column temperature of 30oC26.  
All metabolites were detected across a mass range of 75-1000 m/z using the Exactive mass 
spectrometer at a resolution of 25,000 (at 200m/z), with electrospray (ESI) ionization and 
polarity switching to enable both positive and negative ions to be determined in the same run.  
Lock masses were used and the mass accuracy obtained for all metabolites was below 5ppm.  
Data were acquired with Thermo Xcalibur software (version 2.2). 
The peak areas of different metabolites were determined using Thermo TraceFinder software 
(version 3.2) where metabolites were identified by the exact mass of the singly charged ion 
and by known retention time on the HPLC column.  Commercial standards of all metabolites 
detected had been analysed previously on this LC-MS system with the pHILIC column.  The 
13C labelling patterns were determined by measuring peak areas for the accurate mass of each 
isotopologue of many metabolites.  Intracellular metabolites were normalized to protein 
content of the cells, measured at the end of the experiment by the Lowry assay 27.   As the 
proteins have precippitated on the addition of the metabolite extraction solvent, protein 
contents are measured in the exact same wells as the metabolites have been extracted. 
Translation assay 
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Cells at 50% confluency were pretreated with or without 25mM mannose for 24h or with 
100g/ml cycloheximide for 1 hour. 1MBq 35S methionine (Perkin Elmer, EasyTag™ 
EXPRESS35S Protein Labeling Mix, cat no NEG772002MC ) was added to the culture 
medium, 2ml/well, 6 well plate for 30 min. Cells were washed in ice cold PBS, then lysed in 
lysis buffer (10mM Tris pH 7.5, 50mM NaCl, 0.5% NP40, 0.5% SDS, benzonase (Sigma cat 
no: E1014, 2ul/10ml lysis buffer). Proteins were precipitated in 25% trichloroacetic acid 
(TCA) at 4oC for 30 minutes. TCA precipitates were washed on glass fibre filters (Whatman 
934-AH, cat no 1287-024) with 70% ethanol then acetone and dried and 35S incorporation 
quantitated in a liquid scintillation counter. Results were calculated as relative 35S 
incorporation/105 cells.  
Transcription assay 
Cells at 50% confluency were pretreated with or without 25mM mannose for 24h or with 
5M Actinomycin D for 1 hour. 1.1MBq 32P UTP (Perkin Elmer, cat no:BLU007H001MC ) 
was added to the culture medium, 2ml/well, 6 well plate for 6 hours. Cells were washed in 
PBS and mRNA prepared using the Dynabeads mRNA DIRECT Kit (Life Technologies, cat 
no:61012). 32P labelled mRNA was quantitated in a liquid scintillation counter and results 
were calculated as relative 32P UTP incorporation/105 cells. 
PMI enzymatic assay 
Cells were grown to confluence, washed with PBS and collected by centrifugation 5 min 150 x g. 
at 4 C. Cell pellets were lysed by 3 freezing/thawing cycles. 40g of post-nuclear protein 
fractions were used to determine PMI activities in each cell line tested by means of a coupled 
enzymatic reaction. Briefly, samples were incubated in a buffer containing 200mU of 
Phosphoglucose isomerase (PGI) (Roche, cat#10 127 396 001), 500mM Glucose 6 phosphate 
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dehydrogenase (G6PDH), 1mM NADP +, 40mM Tris-HCl, pH 7.4, 6 mM MgCl2, 5 mM 
Na2HPO4/KH2PO4. Reactions were initiated by addition of 1mM mannose 6 phosphate, and the 
production of NADPH/H+ was assessed for 2h at room temperature by measuring the O.D at 
340nm. In parallel, western blots directed against PMI and ERK2 were performed to examine the 
correlation between PMI activities and PMI expression levels in each cell line analysed. 
 
Proteasome assay 
Cells were seeded 24h prior to 24h treatments using media supplemented or not with 25mM 
mannose. A luminescence-based assay (Proteasome-GloTM Chymotrypsin-like Cell-based Assays, 
Promega) was performed according to manufacturer’s protocol. The measured proteasome 
activities were normalised to cell number by counting cells at the end of each experiment.  Cells 
were treated with 10M MG132 as a control for the specificity of the assay. 
 
Lowry assay 
Lowry assay was used to determine the total protein content for each one of the triplicates 
from the metabolic experiments. First, 500µL of solution A (70% milliQ water, 20% NaOH 
5N, 10% 2,5-Dimethoxy-4-chloroamphetamine) were added to each well from a 6-well plate 
and left under agitation for 20 min. After this, 5mL of solution B (0.5g NaCu-EDTA, 40g 
Na2CO3, 8g NaOH for 2 litres) were added to each well and left for 40 min. Lastly, 500µL of 
Folin reagent were added to each well and left for a minimum of 15 min until colour blue is 
observed in each well. Also, one or two 6-well plates were used for generation of a protein 
concentration standard curve with BSA. 
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Finally, 200µL of each well were separately transferred to a 96-well plate and absorbance 
was measured at 750nm. Then, protein concentration was measured by calculating the 
equation of the standard curve and extrapolating the absorbance of each well. 
Flow cytometry 
Flow cytometry for unfixed cells (cell death assay) was conducted as previously described28, 
and a FACSCalibur or ATTune NXT flow cytometer was used for the analysis. 
Animal experiments 
All in vivo xenograft experiments were performed using 6-week old female CD1-nude mice 
or C57/BL6J wild-type mice as approved by the Glasgow University Animal Welfare and 
Ethical Review Body and in accordance with UK Home Office guidelines. Mice were placed 
5 per cage with access to water and food (chow diet) ad libitum.  Experimental cohort sizes 
were based on previous similar studies that have given statistical results while also respecting 
limited use of animals in line the 3R system: Replacement, Reduction, Refinement.  In no 
case were animals maintained once the tumour size limit permitted in our Home Office 
license (15mm in any diretion) was reached.  All treatment studies were randomized, but did 
not involve blinding.   
KP-4 cells were injected subcutaneously with 100µL of matrigel containing 5 million cells in 
either the right flank or both left and right flanks. LLC and B16-F1 cell were injected 
sucutaneously in PBS suspension with 200L (LLC, 1x106 cells) and 100L (B16-F1, 1x106 
cells) Mice were weighted and tumours were measured using callipers thrice per week 
(usually on Monday, Wednesday and Friday of each week). Calculation of tumour volume 
was as follows: (L x S2)/2 (L: longest length; S: shortest length). 
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For mannose treatment, normal drinking water was exchanged for 200mL of 20% mannose in 
drinking water (w/v) and it was replaced once every week. Mice received mannose by oral 
gavage (200µL) 3 times per week from the same stock of 20% mannose in water. 
For doxorubicin treatments, mice received intraperitoneal injections at a concentration of 
5mg/kg for each mouse once per week. Stocks of 1mg/mL doxorubicin (Sigma, D1515) were 
prepared in milliQ water.  
For azoxymethane (AOM) / dextran sodium sulphate (DSS) experiments, mice were injected 
with a single dose of AOM (Sigma, A5486) at 10mg/kg. Five days after AOM injection, mice 
received 3 cycles of 1.5% DSS (MP Biomedical, 0216011080) in water for 5 days per cycle 
with one week in between each cycle. In the week between each cycle, mice received normal 
water or 20% (w/v) mannose water. After the last cycle of DSS, mice were kept with normal 
water or mannose for two weeks before being culled at day 68. 
Tissue harvest 
All mice were culled by CO2 mediated euthanasia29 before harvesting any tissue sample. 
Mice were put in a cage for exposure to CO2 for 100 seconds before neck dislocation. 
Xenografted tumours were removed and detached from the skin and cut in half. One half of 
each tumour was fixed for 24-30 hours in 10% neutral buffered formalin at room 
temperature. Formalin was then exchanged for 70% ethanol prior to histology. 
The colons of mice from AOM/DSS carcinogenesis experiments were collected and fixed in 
formalin for histological processing. 
For CRC GEMM – male and female VillinCreER Apcfl/+ KrasG12D/+ mice30 aged 6-12 weeks 
were given a single intraperitoneal injection of 80m/kg tamoxifen  (Sigma, T5648). Four days 
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post-induction drinking water was excahnged for 20% mannose in drinking water (w/v) or 
given drinking water ad libitum, this was replaced every week. Mice were aged until clinical 
end-point – when they displayed anaemia, hunching or weight loss. Colons were pinned out 
into 10% neutral buffered formalin and the number of colons counted.  
Blood sampling and blood metabolic extraction 
To measure blood mannose levels tail tipping was performed. Blood samples were directly 
frozen using dry ice and stored at -80⁰C until metabolic extraction was performed. 
For metabolic extraction of whole blood, 2-5µL of each sample were diluted in 100-250µL of 
metabolic extraction buffer on ice for 5 min (1:50 dilution). Then, all samples were 
centrifuged at 13000rpm at 4⁰C for 15 min. Finally, 100µL of the supernatant from each 
sample was transferred into HPLC vials and stored at -80°C until LC-MS analysis.  
PET-MRI scanning 
Mice with KP-4 cells xenografts (n=9, weight 24.6+1.8g) received either 200µL of 20% w/v 
mannose in water (treatment group) or normal water (control group) by oral gavage 20min 
before 18F-FDG injection. 18F-FDG (12.9+1MBq) in 200µl of normal saline was administered 
via an intravenous (i.v.) bolus injection in tail vein. After an uptake phase of 30 min, positron 
emission tomography (PET) and magnetic resonance imaging (MRI) scans were sequentially 
performed using a nanoScan (Mediso Ltd.) PET/MRI (1T) scanner. Mice were maintained 
under 2-2.5% isoflurane in medical air during injection and imaging procedures periods. 
Static PET acquisitions were performed for 15 min and after that whole body T1 GRE 3D 
Multi-FOV MRI scans (slice thickness 0.50mm, repetition time (TR) 10msec, Echo time 
(TE) 2.3msec, flip angle 12 degress) performed to obtain anatomical references.  For 
quantitative assessments of scans, regions of interest (ROI) were manually drawn around the 
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edge of the tumour xenograft on MRI scans by visual inspection using PMOD software 
version 3.504 (PMOD Technologies Ltd.) and same ROI copied on respective PET scans. 
Tumours ROIs were slightly different between scans depending on the positions and angles 
of the mice on the scanner therefore separate ROIs for each scan were drawn. The percentage 
injected dose per gram (%ID/ml) was calculated using formula: %ID/ml = ROI activity 
(kBq/ml) divided by injected dose multiplied by 100%. Data were reported as average % 
ID/ml + SD. Student’s t-tests were used when comparing data between mannose treated and 
control mice.  
Immunohistochemistry – Tissue Microarray PMI staining 
TMAs were first placed in xylene for 5 min before three washes for 1 min each (two in 
ethanol and one in 70% ethanol). TMAs were washed for 5 min in deionised water before 25 
min at 98⁰C in PT module pH 6 sodium citrate retrieval buffer. They were further washed 
once in tris buffered tween (TbT) before blocking endogenous peroxidase for 5 min. TMAs 
were washed again using TbT and stained with PMI antibody (1C7) 1/50 dilution for one 
hour. TMAs were washed in TbT before and after 30 min on Mouse EnVision. 10 min 
incubation in 3,3’-diaminobenzidine tetrahydrochloride was perfomed. TMAs were again 
washed with dionised water (for 1 min) before and after Haematoxylin Z incubation with 
post-incubation with 1% acid alcohol. This was followed by a 30 seconds wash with dionised 
water followed by 1 min incubation with scotts tap water substitute and another minute with 
dionised water. 
Immunohistochemistry – BrdU staining 
Xenografted tumours were embedded in paraffin and cut in sections at appropiate thickness 
before placing the section at 60⁰C overnight. Sections were first placed in xylene for 5 min 
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before three washes for 1 min each (two in ethanol and one in 70% ethanol). Sections were 
washed for 5 min in deionised water before 25 min at 98⁰C in PT module pH 6 sodium citrate 
retrieval buffer. They were further washed once in tris buffered tween (TbT) before blocking 
endogenous peroxidase for 5 min. Sections were washed in TbT before and after incubation 
with BrdU antibody (BD Biosciences #347580, 1/200 dilution) for 35 min. Sections were 
washed in TbT before and after 30 min on Mouse EnVision. 10 min incubation in 3,3’-
diaminobenzidine tetrahydrochloride was perfomed. Sections were agains washed with 
dionised water (for 1 min) before and after Haematoxylin Z incubation with post-incubation 
with 1% acid alcohol. Quick wash of 30 seconds with dionised water followed by 1 min 
incubation with scotts tap water substitute and another minute with dionised water. 
Tissue Microarrays 
TMAs from ovarian, breast, colorectal, prostate and renal cancer were stained for 
phosphomannose isomerase (PMI). TMAs were scanned using Leica Biosystems and were 
scored for PMI expression based on the percentage of tumour that showed negative, low, 
medium or high expression. Each sample was scored with a number between 0-300 following 
this equation: Score=(0 x negative) + (1 x low) + (2 x medium) + (3 x high).  
Statistical analysis and Reproducibility. 
All data presented were analysed using GraphPad Prism software. Three different statistical 
analyses were performed depending on the data from the different experiments shown. 
Generally, one-way ANOVA, two-way ANOVA, Log-Rank (Mantel-Cox) test and Student’s 
t-test that could be paired or unpaired and one-tailed or two-tailed. Three levels of 
significance were determined: *p < 0.05, **p < 0.01, ***p < 0.001, ****P<0.0001, ns = no 
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significant.  Where a representative experiment is shown, the number of times the same result 
was observed in independent experiments is detailed in the corresponding figure legend. 
Data Availability 
Data that support the findings in this study are stored at the Cancer Research UK Beatson 
Institute and are available from the corresponding author upon reasonable request. 
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Extended Data Figures:   
Extended Data Figure 1: (a). Growth curves of Saos-2 cells supplemented without (Ctrl) or 
with 25mM of hexoses (Man, mannose; Gal, galactose; Fru, fructose; Fuc, fucose; Glc, 
glucose). (b-d) Growth curves of (b) PA-TU-8902 and (d) A549 cells in DMEM (-Man) or 
with additional 25mM mannose (+Man); (c) K562 cells in 10% FBS RPMI medium with or 
without 11.1mM mannose. (e) Western blotting showing the levels of phospho-AMPKα 
(T172) and total AMPKα after 5, 15, 30 and 45 min incubation of U2OS with 25mM 
mannose-supplemented or regular medium. (f) Growth curves of SKOV3 and RKO cells in 
DMEM (-Man) or with additional 25mM mannose (+Man). (g) Levels (peak area per 
microgram of protein) of 2-deoxyglucose-phosphate (2-DG-P) in RKO, SKOV3, SAOS-2 
and U2OS cells incubated with 10mM 2-deoxyglucose for 6h in the presence of 25 mM 
mannose in the culture medium (DMEM). Data represent the average of three technical 
replicates.  (h) Percentage of peak area per microgram of protein (log-10 scale) of hexoses-6-
phosphate in U2OS cells after 6h incubation in 10% dialyzed FBS 5mM glucose DMEM with 
or without 5mM mannose. (i) Peak area per microgram of protein of hexoses-6-phosphate in 
U2OS cells incubated for 6 hours in DMEM with or without additional 25mM of sugars 
(Man, mannose; Gal, galactose; Fru, fructose; Fuc, fucose; Glc, glucose). (j,k) Peak area per 
microgram of protein of intracellular non-phosphorylated (j) mannose or (k) glucose after 6 
hours incubation of U2OS cells in 5mM glucose DMEM with or without 5mM mannose. (l) 
Peak area per microgram of protein of non-phosphorylated glucose m+2 after 6 hours 
incubation of U2OS cells in glucose-free DMEM with 5mM 1,2-13C2-D-glucose alone and 
with or without 5mM 13C6-D-mannose. (m-p) Peak area per microgram of protein of (m) 
glyceraldehyde-3-phosphate (GA3P), (n) phosphoenolpyruvate (PEP), (o) lactate and (p) 
UDP-N-Acetyl-glucosamine (UDP-GlcNAc) in U2OS cells after 6 hours incubation in 
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DMEM with or without additional 25mM of other sugars (Man, mannose; Gal, galactose; 
Fru, fructose; Fuc, fucose; Glc, glucose). n=3 independent experiments 
(a,b,c,d,f,h,i,j,k,l,m,n,o,p).   Data are representative of 2 independent experiments (e).  In all 
data error bars represent mean +/- S.E.M..  Data were analysed by (i,m,n,o,p) one-way 
ANOVA, (a) two-way ANOVA followed by Tukey's multiple comparisons or (h,j,k,l) paired 
two-tailed Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001.  
 
Extended Data Figure 2:    (a) Levels (peak area per microgram of proteins) of 2-deoxy-2-
fluoro-D-mannose-phosphate (2-DFM-P) in RKO, SKOV3, SAOS-2 and U2OS cells after 6 
hours treatment with or without 2mM 2-deoxy-2 fluoro-D-mannose. Relative levels of 
exoses-6-phosphate (b), lactate (c), glyceraldehyde-3-phosphate (d), phosphoenolpyruvate 
(e), malate (f), ribose-5-phosphate (g) uridine diphosphate N-acetylglucosamine (UDP-
GlcNac) (h) in SKOV3 and U2OS cells after 6 hours treatment with (+ Man) or without (- 
Man) 25 mM mannose in the culture medium (DMEM). Data in (a) represent the average of 
three technical replicates.  (b-h) n=2 independent experimenst (each involving technical 
triplicates). In all data error bars represent mean +/- S.E.M.. 
 
Extended Data Figure 3: 
Content (peak area per microgram of proteins) of (a) Hexoses-6-phosphate (Hexoses-6P), (b) 
ATP, (c) AMP, (d) Fructose 1,6-bisphosphate (F1,6-BP), (e) Ribose-5-phosphate (Ribose 5P) 
and (f) uridine diphosphate N-acetylglucosamine (UDP-GlcNac) in U2OS cells after 5 
minutes treatment with (+ Man) or without (- Man) 25 mM mannose in the culture medium 
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(DMEM). n=3 independent experiments, presented as mean ± S.E.M. and analyzed by two-
tailed unpaired t-test. *P < 0.05, ***P < 0.001. 
 
Extended Data Figure 4: (a-b) Percentage of PI-positive KP-4 cells after 24 h treatment 
with (a) 40µM cisplatin or (b) 1µg/mL doxorubicin in the presence or absence of 25mM 
mannose. (c) Percentage of U2OS PI-positive cells after 24 h treatment with or without 10µM 
cisplatin in DMEM with or without 25mM of additional sugars (Man, mannose; Gal, 
galactose; Fru, fructose; Fuc, fucose; Glc, glucose). (d) Percentage of U2OS PI-positive cells 
after 24 h treatment with or without 1µg/mL doxorubicin, with or without 25mM mannose 
and with or without 50µM zVAD-fmk. (e-f) Fold increase of the percentage of PI-positive 
Saos-2 (NTC, caspase-8 and FADD CRISPR) cells upon 24 hours treatment in DMEM with 
or without 1µg/mL doxorubicin (e) or 10M cisplatin (f) and with or without 25mM 
mannose. (g) Western blotting showing the levels of caspase-8, FADD and ERK2 in NTC, 
caspase-8 and FADD CRISPR Saos-2 cells. (h) Percentage of Empty and Bax/Bak CRISPR 
U2OS PI-positive cells with or without 1µg/mL doxorubicin and with or without 25mM 
mannose. (i) Western blotting showing the levels of Bax, Bak and HSP90 in Empty and 
Bax/Bak CRISPR U2OS cells. (j) Western blot showing the levels of Bim, Noxa, Bad, Bax, 
Actin and HSP-90 in U2OS cells after 24 hours treatment with or without 10µM cisplatin, 
with or without 25mM mannose and with or without 50µM zVAD-fmk. The HSP-90 blot is 
identical to the one shown in Fig 2h as the the blots are from the same experiment. (k) 
Western blotting showing the levels of Mcl-1 and Bcl-XL in U2OS cells after 48 h with or 
without 10µM cisplatin, with or without 25mM mannose and in the absence or presence of 
10M MG132 as indicated. (l-m) qRT-PCR showing the levels of (l) BCL2L1 (Bcl-XL) and 
(m) MCL1 mRNAs in U2OS cells after 48 h treatment with or without 10µM cisplatin, with 
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or without 25mM mannose in the presence of 50M zVAD-fmk.  (n-o) Percentage of U2OS 
Emtpy, Mcl-1 and Bcl-XL overexpressing PI-positive cells after 24 hours treatment with or 
without 1µg/mL doxorubicin and with or without 25mM mannose. (p-q) Western blot 
showing the levels of Mcl-1, Bcl-XL and HSP-90 in U2OS Emtpy, Mcl-1 and Bcl-XL 
overexpressing cells. n=3 independent experiments (a,b,c,e,f,h,l,m,n,o).  Data are 
representative of two independent experiments (g,j,k) or one experiment (i,p,q).  In (d), n =3 
independent experiments (each involving technical triplicates) (-zVAD-fmk) and n=2 
independent experimenst (each involving technical triplicates) (+zVAD-fmk).  In all data, 
error bars represent mean +/- S.E.M..  Data were analysed by (a,b,c,d,e,f,h,n,o) two-way 
ANOVA with Bonferroni correction. *P < 0.05, **P < 0.01, ***P < 0.001.  
 
Extended data Figure 5: Sensitization to cell death by mannose is connected to Bcl-2 
family memebers.  (a) Percentage of control (NTC) and Noxa CRISPR U2OS PI-positive 
cells upon 24h treatment with or without 10M cisplatin and with or without 25mM 
mannose.  (b) Percentage of U2OS PI-positive cells upon 24hr treatment with 10M 
WEHI539, a BclXL inhibitor, or 10M ABT-199, a Bcl-2 inhibitor, with or without 25mM 
mannose.  n=4 independent experiments (a) or n=3 three independent experiments (b).  In all 
data. error bars represent mean +/- S.E.M..  Data were analyzed by two-way ANOVA with 
Bonferonni correction (a) and two-tailed unpaired t-test (b).  ****P<0.0001; ns, not 
significant.   
 
Extended data Figure 6: (a) Mannose levels in the plasma after 60 min in mice treated with 
a single dose of 200µL of water (-Man) or 20% mannose in water (w/v) (+Man). (b-c) CD1-
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nude mice were transplanted with KP-4 cells subcutaneously and tumours were grown for 14 
days.  PET-MRI scans were performed for mice treated with 200µL of water (-Man) or 20% 
(w/v) mannose in water (+Man) by oral gavage 20 min before 18F-FDG tail vein injection. (b) 
Quantification of 18F-FDG uptake by tumours represented in average % ID/mL +/- SD. (c) 
Tumour volume (mm3) of each tumour at the moment of the PET-MRI scan. Data were 
analyzed by unpaired two-tailed Student’s t-test. (d) CD1-nude mice were injected with KP-4 
cells subcutaneously and treated with normal drinking water (-Man) or 20% mannose in the 
drinking water (w/v) plus the same treatment via oral gavage 3 days per week from the 3rd 
day after tumour transplantation. Shown is the quantification of 18F-FDG uptake by tumour 
and different organs represented in averaged kBq/mL +/- SD. Data were analyzed by 
unpaired two-tailed Student’s t-test.  (e) CD1-nuce mice were injected with KP-4 cells 
subcutaneously and treated with normal drinking water (-Man) or 20% mannose in the 
drinking water (w/v) plus the same treatment via oral gavage 3 days per week from the 3rd 
day after tumour transplantation. Mouse weights were recorded at the indicated times. (f,g) 
CD1-nuce mice were injected with KP-4 cells subcutaneously and treated with normal 
drinking water (-Man) or 20% mannose in the drinking water (w/v) plus the same treatment 
via oral gavage 3 days per week from the 3rd day after tumour transplantation. Images of 
BrdU sections representing tumours in control (-Man) and mannose-treated (+Man) mice (f). 
(g) Quantification of BrdU-positive cells per section in n=4 control tumours (-Man) and n=4 
mannose-treated tumours. 5 representative pictures per tumour were analysed. (h) CD1-nude 
mice were injected with KP-4 cells subcutaneously and tumours were grown for 10 days 
before treatment mannose (Man) and/or doxorubicin (Doxo) was started. Mice received 
normal drinking water (Ctrl and Doxo) or 20% mannose in the drinking water (Man and 
Doxo + Man) together with the same treatment by oral gavage thrice per week. Doxorubicin 
treatment started on day 32 and mice received 5mg/kg by IP injection once per week. Mouse 
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weight in all groups throughout the experiment (h).  Mice number for each experiment is (a) 
n=3 animals per group, (b-d) n=5 animals per group, -Man; n=4 animals per group, +Man, 
(h) n=10 animals/group.  In a,c and h error bars represent mean +/- S.E.M..  Data were 
analysed with a two-tailed unpaired t-test (c).  *P < 0.05, **P < 0.01 
 
Extended data Figure 7: (a) PMI expression levels correlate with PMI activities.  PMI 
activities were measured in 8 different cell lines using coupled enzymatic reactions. Graph shows 
the OD 340nm measured at 2h reflecting the amount of NADPH/H+ produced by the reactions. 
Results from 3 independent experiments were normalised relative to PMI activities measured in 
Saos-2 cells and represent means +/- SEM. (b-g) PMI knockdowm senstizes cells to mannose.  
(b) Western blot of SKOV3 transfected cells showing the levels of PMI and actin after 48 h 
of transient transfection with siRNAs. Growth curves of (c) SKOV3, (f) RKO and (g) 
IGROV1 in regular DMEM supplemented with or without 25mM mannose after transient 
transfection for 48 hours with 2 NTC and 2 PMI targeting siRNAs. (d,e) Western blot 
showing the levels of PMI and ERK2 in (d) RKO and PMI and actin in (e) IGROV1 48h post 
siRNA transfection. (h-k)  Over-expression of PMI causes resistance to the growth 
suppressing and death–promoting effects of mannose.  PMI expression in U2Os (h) and Saos- 
(i) was confirmed by western blotting. (j) Saos2-PMI cells and Control cells (Saos-2) were 
plated in the presence (+Man) or the absence (-Man) of 25mM mannose and cell numbers 
counted at the times indicated.    (k) Percentage of PI-positive U2OS control cells (V) or 
U2OS cells overexpressing PMI (PMI) after 24h treatment with or without 1g/ml 
doxorubicin in the presence or absence of 25mM mannose.  (l-o) Percentage of (l) lactate, 
(m) glyceraldehyde-3-phoshate (GA3-P), (n) α-ketoglutarate (α-KG) and (o) malate 
metabolic content in SKOV3 transfected cells with siRNA for 48 hours before 6 h incubation 
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in complete DMEM medium with or without supplementation of 25mM mannose. n=3 
independent experiments (a,c,f,g,j,l,m,n,o).  Data are representative of two independent 
experiments (b,d,e,k), or one experiment (h,i).    In all data, error bars represent mean +/- 
S.E.M.. Data were analyzed by (a) two-tailed unpaired t-test (l,m,n,o) two-way ANOVA with 
Tukey correction, (j) Multiple unpaired two-sided t-test with Holm-Sidak correction. 
*P<0.05, ***P<0.001, ****P < 0.0001.  
 
Extended Data Figure 8: (a-b) PMI knockdown causes growth retardation upon mannose 
treatment in a dose-dependent manner. B16-F1 cells infected with non-targeting control 
(NTC) or PMI shRNA were treated with (blue columns) or without (white columns) 25mM 
mannose for 72h when cell number was then determined (a) Results are shown as mean ± 
S.E.M. n=3 independent experiments. PMI knockdown was confirmed by western blotting 
(b).  (c) Western blot showing PMI knockdown in LLC cells.  The data are relative to the 
experiment shown in Figure 4c.  (d) B16-F1 cells infected with non-targeting control (NTC) 
or PMI shRNA were treated with 25 mM Mannose (Man), 25 mM Glucose (Glc), 25 mM 
Galactose (Gal), 25 mM Fructose (Fru), 25 mM Fucose (Fuc). At 24, 48, and 72h after 
hexose treatment, cell number was determined. The results are shown as mean ± S.E.M..  (e-
h)  Weights of mice injected with syngeneic cells lines: B16 shNTC (e), B16 shPMI (f), LLC 
shNTC (g) and LLC shPMI (h) which had been given drinking water (-Man) or drinking 
water supplemeneted with 20% mannose (+Man) (n=10 mice per group).  All date are mean 
+/- S.D. unless otherwise stated.  In d) n=4 independent experiments which were analysed by 
two-way ANOVA followed by Tukey's multiple comparisons.  The data in b and c were only 
performed once.  ***P<0.001 
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Extended data Figure 9: (a) Images of PMI expression for each TMA representing one 
negative sample, one low expression and one high expression. One sample came from each of 
the ovarian, breast, prostate, colorectal or renal TMAs. (b,c) Kaplan Meier curves showing 
cancer specific survival based on PMIlevles in (b) n=698 patients with stage I-IV colorectal 
cancer or (c) n=316 patients with primary operable breast cancer. (d) Table showing 
association of PMI and cancer specific survival. Histoscores were split into high and low 
expression using the ROC curve analysis for each tumour type.   Log-rank analysis (two-
sided) was used to compare PMI and cancer specific survival using SPSS (version 22). (e) 
Weight of 28 mice during the treatments of AOM/DSS with or without additional mannose 
treatment. (f) Weight of aged VillinCreER Apcfl/+ KrasG12D/+ mice during treatment with or 
without mannose. Data represented as mean of each group (n=7 animals, - Man; n=8 animals, 
+ Man). 
 
Extended Data Figure 10:  Mannose does not affect amino acid and fatty acid uptake 
nor does it significantly affect serine and glycine levels, ER stress or proteasome 
activity, but it does affect autophagy, transcription and translation in a PMI-dependent 
manner.  (a) Exchange rates of amino acids between the indicated cells and their media 
measured after 48 hours treatment with (+ Man) or without (- Man) 25 mM mannose. Results 
are presented as Peak Area per micrograms of proteins per hour and are representative of one 
experiment.  Shown is the mean of 6 technical replicates. (b) Levels of 13C16-Palmitate 
(expressed as peak area per micrograms of proteins) in U2OS cells incubated with 50 µM 
13C16-Palmitate, conjugated with 10% fatty acids-free bovine serum albumin (BSA), for 24 
hours in the presence (+) or absence (-) of 25 mM mannose in the culture medium (DMEM). 
n=2 independent experiments (each involving 6 technical replicates).  Data are presented as 
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mean ± S.E.M. Levels of 13C3-Serine (c) and 13C2-Glycine (d) (expressed as peak area per 
micrograms of proteins) in U2OS cells incubated with 25 mM 13C6-Glucose for the indicated 
time in the presence (+ Man) or absence (- Man) of 25 mM mannose in the culture medium 
(DMEM). n=3 independent experiments.  Isotopologues distribution of intracellular Serine 
(e) and Glycine (f) in U2OS cells incubated with 25 mM 13C6-Glucose for 24 hours in the 
presence (MANNOSE) or absence (CTR) of 25 mM mannose in the culture medium 
(DMEM). n=3 independent experiments.  (g) Mannose has no effect on the unfolded protein 
response.  U2OS E1A cells were treated with 25 mM D-(+)-Mannose (Man) for 16 and 24 h. 
2-Deoxy-D-glucose (2DG) and Tunicamycin (TM) serve as positive controls. Induction of 
Bip/GRFP78 (Bip) is a readout of ER stress.  The data are representative of three independent 
experiments.   (h) Proteasome activity is not affected by mannose.  Mannose-sensitive U2OS 
cells were incubated in either DMEM or DMEM containing 25 mM mannose prior to 
measurement of proteasome activities.  Cells were also treated with10 M MG132 as a 
control for proteasome activity. n=3 independent experiments. (i,j) U2OS cells (i) or U2OS 
cells over-expressing PMI (j) were treated with 25 mM D-(+)-Mannose (Man) for the 
indicated times in the presence or absence of 20 M Chloroquine (CQ) (4 hr). Western 
blotting was undertaken to detect LC3-B and actin.  The data are representative of three 
independent experiments. (k,l) Relative incorporation of 32P UTP (k) or 35S methionine (l) 
into U2OS control cells (vector) or U2OS cells overexpressing PMI (PMI) in the presence or 
absence of 25mM mannose.  Where indicated 5M Actinomycin D was used to inhibit 
transcription or 100g/ml cycloheximide was used to inhibit translation.  (m,n) U2OS E1A 
cells infected with lentiCRISPR-NTC 1, NTC 2, ATG5, or ATG7 were treated with 25 mM 
D-(+)-Mannose (Man) for 72h before cell counting (m). The results are shown as mean and 
represent representative one independent experiment performed in triplicate. (n) Western 
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blots show loss of LC3 lipidation and p62 accumulation in ATG5 and ATG7 knockout cells.  
In k, n= 3 independent experiments.  In l n=3 independent experiments (control and 
mannose) and n=2 independent experiments (CHX).  Data were analyzed by two-tailed 
unpaired t-tests.  *P<0.05, ***P<0.001.  Unless otherwise stated, data respresent mean +/- 
S.E.M.. 
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